Øvrebotten, Tarjei
Mecinaj, Albulena
Stavem, Knut
Ghanima, Waleed
Brønstad, Eivind
Durheim, Michael T
Lerum, Tøri V.
Josefsen, Tony
Grimsmo, Jostein
Heck, Siri L.
Omland, Torbjørn
Ingul, Charlotte B.
Einvik, Gunnar
Myhre, Peder L.
Funding for this research was provided by:
University of Oslo
Article History
Received: 8 August 2023
Accepted: 21 March 2024
First Online: 13 April 2024
Declarations
:
: This study was approved by the Regional Ethics Committee for South-Eastern Norway (#20/02873; #20/05884; #125384). Informed consent was obtained from all participants, which was given by returning a written signed consent form. Data was stored and post-processed in Services for Sensitive Data (TSD; University of Oslo), in compliance with the Norwegian Personal Data Act and Health Research Act.
: Not applicable.
: P.L.M has served on advisory boards and/or received speaker fees from Amarin, AmGen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Pharmacosmos, Vifor and Us2.ai, unrelated to this work. C.I and J.G have received fees for lectures from Bayer AG. J.G has received fees for participating in an expert panel from Sanofi, unrelated to this work. S.A. has received speaker honoraria from Bayer and Novartis. T.O. has received consultancy and speaker honoraria from Abbott Diagnostics, Roche Diagnostics, and Novartis, and research support via Akershus University Hospital from Thermo Fisher BRAHMS, HyTest Ltd., Biomedica, Abbott Diagnostics, Novartis, Singulex, SomaLogic, and Roche Diagnostics. T. O. also has financial interests in Cardinor AS, which holds the license to commercialize secretoneurin. Waleed Ghanima reports fees for participation in Advisory board from Amgen, Novartis, Pfizer, Principia Biopharma Inc- a Sanofi Company, Sanofi, SOBI, Grifols, UCB, Argenx, Cellphire. Lecture honoraria from Amgen, Novartis, Pfizer, Bristol Myers Squibb, SOBI, Grifols, Sanofi, and Bayer, and have received research grants from Bayer, BMS/Pfizer, and UCB. All other authors report no disclosures.